Drug Profile
Research programme: metastin - Takeda
Latest Information Update: 18 May 2010
Price :
$50
*
At a glance
- Originator Takeda
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 12 Feb 2004 This compound is still in active development
- 04 Jul 2001 Preclinical development for Cancer in Japan (Unknown route)